78 related articles for article (PubMed ID: 24354546)
1. Does the new formulation of OxyContin® deter misuse? A qualitative analysis.
Buer LM; Havens JR; Leukefeld C
Subst Use Misuse; 2014 May; 49(6):770-4. PubMed ID: 24354546
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
[TBL] [Abstract][Full Text] [Related]
3. Transition from first illicit drug use to first injection drug use among rural Appalachian drug users: a cross-sectional comparison and retrospective survival analysis.
Young AM; Havens JR
Addiction; 2012 Mar; 107(3):587-96. PubMed ID: 21883604
[TBL] [Abstract][Full Text] [Related]
4. The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study.
Degenhardt L; Bruno R; Ali R; Lintzeris N; Farrell M; Larance B
Drug Alcohol Depend; 2015 Jun; 151():56-67. PubMed ID: 25910850
[TBL] [Abstract][Full Text] [Related]
5. OxyContin® as currency: OxyContin® use and increased social capital among rural Appalachian drug users.
Jonas AB; Young AM; Oser CB; Leukefeld CG; Havens JR
Soc Sci Med; 2012 May; 74(10):1602-9. PubMed ID: 22465379
[TBL] [Abstract][Full Text] [Related]
6. Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential.
Sellers EM; Perrino PJ; Colucci SV; Harris SC
J Psychopharmacol; 2013 Sep; 27(9):808-16. PubMed ID: 23784739
[TBL] [Abstract][Full Text] [Related]
7. A profile of OxyContin addiction.
Hays LR
J Addict Dis; 2004; 23(4):1-9. PubMed ID: 15339710
[TBL] [Abstract][Full Text] [Related]
8. A comparison of rural and urban nonmedical prescription opioid users' lifetime and recent drug use.
Young AM; Havens JR; Leukefeld CG
Am J Drug Alcohol Abuse; 2012 May; 38(3):220-7. PubMed ID: 22211586
[TBL] [Abstract][Full Text] [Related]
9. Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.
Gosai P; Ducharme MP; Godfrey AR; Freeman JC; Monif T; Kumar KS; Kumar S; Mudnaik R; Katikaneni P
Int J Clin Pharmacol Ther; 2013 Nov; 51(11):895-907. PubMed ID: 23673291
[TBL] [Abstract][Full Text] [Related]
10. OxyContin use and misuse in three populations: substance abuse patients, pain patients, and criminal justice participants.
Wunsch MJ; Cropsey KL; Campbell ED; Knisely JS
J Opioid Manag; 2008; 4(2):73-9. PubMed ID: 18557163
[TBL] [Abstract][Full Text] [Related]
11. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).
Cicero TJ; Dart RC; Inciardi JA; Woody GE; Schnoll S; Muñoz A
Pain Med; 2007 Mar; 8(2):157-70. PubMed ID: 17305687
[TBL] [Abstract][Full Text] [Related]
12. An iterative model for in vitro laboratory assessment of tamper deterrent formulations.
Cone EJ; Giordano J; Weingarten B
Drug Alcohol Depend; 2013 Jul; 131(1-2):100-5. PubMed ID: 23332441
[TBL] [Abstract][Full Text] [Related]
13. An exploratory study of OxyContin use among individuals with substance use disorders.
Levy MS
J Psychoactive Drugs; 2007 Sep; 39(3):271-6. PubMed ID: 18159780
[TBL] [Abstract][Full Text] [Related]
14. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010.
Severtson SG; Bartelson BB; Davis JM; Muñoz A; Schneider MF; Chilcoat H; Coplan PM; Surratt H; Dart RC
J Pain; 2013 Oct; 14(10):1122-30. PubMed ID: 23816949
[TBL] [Abstract][Full Text] [Related]
15. Trends in controlled-release oxycodone (OxyContin) prescribing among Medicaid recipients in Kentucky, 1998-2002.
Havens JR; Talbert JC; Walker R; Leedham C; Leukefeld CG
J Rural Health; 2006; 22(3):276-8. PubMed ID: 16824176
[TBL] [Abstract][Full Text] [Related]
16. OxyContin misuse on a reservation: qualitative reports by American Indians in talking circles.
Momper SL; Delva J; Reed BG
Subst Use Misuse; 2011; 46(11):1372-9. PubMed ID: 21810072
[TBL] [Abstract][Full Text] [Related]
17. Route of administration for illicit prescription opioids: a comparison of rural and urban drug users.
Young AM; Havens JR; Leukefeld CG
Harm Reduct J; 2010 Oct; 7():24. PubMed ID: 20950455
[TBL] [Abstract][Full Text] [Related]
18. Prescription Opioid Misuse Index: a brief questionnaire to assess misuse.
Knisely JS; Wunsch MJ; Cropsey KL; Campbell ED
J Subst Abuse Treat; 2008 Dec; 35(4):380-6. PubMed ID: 18657935
[TBL] [Abstract][Full Text] [Related]
19. The effect of FDA approval of a generic competitor to OxyContin (oxycodone HCl controlled-release) tablets on the abuse of oxycodone.
Bailey JE; Barton PL; Lezotte D; Lowenstein SR; Dart RC
Drug Alcohol Depend; 2006 Sep; 84(2):182-7. PubMed ID: 16510252
[TBL] [Abstract][Full Text] [Related]
20. Non-medical use of OxyContin Tablets in the United States.
Sees KL; Di Marino ME; Ruediger NK; Sweeney CT; Shiffman S
J Pain Palliat Care Pharmacother; 2005; 19(2):13-23. PubMed ID: 16061457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
